C-Reactive Protein and Response to Adalimumab in Patients With Hidradenitis Suppurativa: A Post Hoc Analysis of 2 Randomized Clinical Trials.
作者信息
Gunter Simon J, Porter Martina L, Kimball Alexa B
机构信息
Department of Medicine, Pennsylvania Hospital, Philadelphia.
Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
出版信息
JAMA Dermatol. 2025 Feb 1;161(2):221-223. doi: 10.1001/jamadermatol.2024.5146.
Abstract
摘要
相似文献
1
C-Reactive Protein and Response to Adalimumab in Patients With Hidradenitis Suppurativa: A Post Hoc Analysis of 2 Randomized Clinical Trials.化脓性汗腺炎患者的C反应蛋白与阿达木单抗反应：两项随机临床试验的事后分析
JAMA Dermatol. 2025 Feb 1;161(2):221-223. doi: 10.1001/jamadermatol.2024.5146.
2
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.化脓性汗腺炎临床反应（HiSCR）：一种用于评估阿达木单抗2期研究安慰剂对照部分中化脓性汗腺炎患者治疗效果的新型临床终点。
J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94. doi: 10.1111/jdv.13216. Epub 2015 Jul 22.
3
4
Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience.阿达木单抗治疗化脓性汗腺炎患者的临床及超声特征：一项单中心真实世界研究
Acta Derm Venereol. 2020 Jun 11;100(13):adv00172. doi: 10.2340/00015555-3520.
5
Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.接受阿达木单抗治疗的化脓性汗腺炎患者的血液学异常
JAMA Dermatol. 2024 Jun 1;160(6):678-681. doi: 10.1001/jamadermatol.2024.1075.
6
Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.阿达木单抗用于治疗化脓性汗腺炎的临床经验。与克罗恩病的缓解率比较。
Actas Dermosifiliogr. 2016 Sep;107 Suppl 2:43-50. doi: 10.1016/S0001-7310(17)30008-X.
7
Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.临床缓解率、安慰剂缓解率和显著相关的协变量取决于化脓性汗腺炎的结局测量选择：PIONEER 1 和 2 个体患者数据的事后分析。
J Am Acad Dermatol. 2020 May;82(5):1150-1157. doi: 10.1016/j.jaad.2019.12.044. Epub 2019 Dec 24.
8
Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting.阿达木单抗联合手术与阿达木单抗单药治疗化脓性汗腺炎的比较：真实世界环境中的一项随机对照试验。
J Am Acad Dermatol. 2023 Oct;89(4):677-684. doi: 10.1016/j.jaad.2023.04.034. Epub 2023 Apr 27.
9
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
10
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.阿达木单抗在中重度化脓性汗腺炎中的中期剂量策略：来自 III 期随机安慰剂对照 PIONEER 试验的综合结果。
Br J Dermatol. 2019 Nov;181(5):967-975. doi: 10.1111/bjd.17919. Epub 2019 Aug 14.
本文引用的文献
1
Increased Doses of Adalimumab are Associated With Clinical Improvement of Hidradenitis Suppurativa.阿达木单抗增加剂量与化脓性汗腺炎的临床改善相关。
J Drugs Dermatol. 2023 Jun 1;22(6):615-618. doi: 10.36849/JDD.6868.
2
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.司库奇尤单抗治疗中重度化脓性汗腺炎（SUNSHINE和SUNRISE研究）：两项相同的多中心、随机、安慰剂对照、双盲3期试验的第16周和第52周结果
Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3.
3
Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.真皮隧道影响阿达木单抗治疗化脓性汗腺炎患者的临床应答时间，家族史影响临床应答丧失时间。
Clin Exp Dermatol. 2021 Mar;46(2):306-313. doi: 10.1111/ced.14448. Epub 2020 Oct 22.
4
The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa.血清促炎细胞因子、C 反应蛋白和红细胞沉降率升高对化脓性汗腺炎患者的临床意义。
Mediators Inflamm. 2017;2017:2450401. doi: 10.1155/2017/2450401. Epub 2017 Jul 10.
5
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.阿达木单抗治疗化脓性汗腺炎的两项 3 期临床试验。
N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.
Zotero 插件